Abstract
Letrozole is a type 2 aromatase inhibitor, which reduces availability of estrogen in postmenopausal women, thereby decreasing its ability to stimulate breast cancer cells. Phase III trials in both the advanced and early breast cancer setting have shown an improvement in disease-free survival compared with other compounds, including tamoxifen. Letrozole is well-tolerated, with the main adverse effects reported as hot flushes, arthritis, arthralgia and myalgia, and a trend towards increased risk of fracture.
MeSH terms
-
Antineoplastic Agents / therapeutic use*
-
Antineoplastic Agents, Hormonal / therapeutic use*
-
Aromatase Inhibitors / therapeutic use
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / prevention & control
-
Chemotherapy, Adjuvant
-
Clinical Trials, Phase III as Topic
-
Female
-
Humans
-
Letrozole
-
Neoplasm Staging
-
Nitriles / therapeutic use*
-
Postmenopause
-
Quality of Life
-
Tamoxifen / therapeutic use
-
Triazoles / therapeutic use*
Substances
-
Antineoplastic Agents
-
Antineoplastic Agents, Hormonal
-
Aromatase Inhibitors
-
Nitriles
-
Triazoles
-
Tamoxifen
-
Letrozole